ARQT

26.3602.98%
AD

Amit D. Munshi

Independent Director

Mr. Amit D. Munshi, MBA, is Independent Chairman of Sensorion SA from April 1, 2025 and served as its Interim CEO since February 17, 2026 until June 01, 2026. Mr. Munshi has been the Director of Inhibikase Therapeutics Inc. since October 21, 2024 and serves as its Chairman since February 14, 2025. He was Chief Executive Officer at Orna Therapeutics, Inc from May 2024 to March 2025. He is former President and CEO of Arena Pharmaceuticals Inc., which he built from market cap into a late clinical stage company before its acquisition. He had been Independent Director at Damora Therapeutics, Inc. (formerly known as Galecto, Inc.) since May 2020. Mr. Munshi served as the Chairman of the Board at Damora Therapeutics, Inc. (formerly known as Galecto, Inc.) since May 2020. Mr. Munshi had been the Chief Executive Officer and President of Arena Pharmaceuticals, Inc. since May 11, 2016 until March 2022. Mr. Munshi serves as Non-Executive Chairman of Enterprise Therapeutics Ltd since March 2019. He serves as Non Executive Chairman at Zura Bio Limited since March 21, 2023. Mr. Munshi served as an Interim Principal Financial Officer of Arena Pharmaceuticals, Inc. from May 11, 2016 to June 15, 2016. Prior to Arena Pharmaceuticals, he served as the Chief Executive Officer, President and Director of EPIRUS Biopharmaceuticals, Inc. from May 2012 to May 6, 2016. Mr. Munshi served as the President and Chief Executive Officer at Percivia LLC (Sold to Johnson & Johnson) from April 2011 to May 2012. He co-founded Kythera Biopharmaceuticals, Inc. in 2005 and served as its Chief Business Officer and Advisor from August 2005 to January 2011. He was an Advisor of Cynvenio Biosystems, Inc. He held leadership positions at Amgen Inc from September 1997 to January 2005. Globally in Multiple Product Management, General Management and Corporate Development Positions from 1997 to 2005, including General Manager of European Nephrology. Mr. Munshi has global biopharmaceutical industry experience in executive management, business development, product development and portfolio management and has served on several private and public company boards. He served as Independent Director at Social Capital Suvretta Holdings Corp. IV since June 29, 2021 until August 04, 2022. Mr. Munshi serves on the boards of Oxeia Biopharmaceuticals, Inc. and Cytrellis Biosystems, Inc., both privately held companies. Mr. Munshi also cofounded Oxeia Biopharmaceuticals, Inc., a clinical-stage biotechnology company, in August 2014. He had been a Director at Arena Pharmaceuticals, Inc. since June 13, 2016 until March 11, 2022. He served as an Independent Director at Pulmatrix, Inc. since June 2017 until April 02, 2021. He served as a Director at Cynvenio Biosystems, Inc. since August 3, 2011. Mr. Munshi holds a BA in History and a BS in Quantitative Economics from the University of California at Riverside and an MBA from the Peter F. Drucker & Masatoshi Ito Graduate School of Management at Claremont Graduate University. He serves on the Board of MPM StealthCo LLC. He serves as an advisor and lecturer at the Peter F. Drucker School of Management at the Claremont Graduate School. He has served as Chief Executive Officer and Chairman of the Board of ReNAgade Therapeutics, a private biotechnology company, since May 2023. He is Independent Director of Arcutis Biotherapeutics, Inc. from December 4, 2025.

Positions